Hyperuricemia is the medical term for having too much uric acid in the blood, typically defined as levels above 6.8 mg/dL, the point at which uric acid starts to crystallize in body tissues at normal temperature. It affects a substantial and growing share of adults worldwide, and while gout is its most familiar consequence, elevated uric acid is tangled up in kidney disease, cardiovascular risk, and metabolic disorders in ways that researchers are still sorting out. Part of the story is evolutionary: humans are one of the few mammals that cannot break uric acid down any further, a quirk that leaves us walking around with blood levels roughly ten times higher than most other species.
Why Humans Are Stuck With High Uric Acid
Most mammals have a working enzyme called uricase that converts uric acid into allantoin, a much more soluble compound that the kidneys flush out easily. Humans, great apes, and (oddly) Dalmatian dogs are the major exceptions. In our case, the gene for uricase was knocked out by a series of mutations during the Miocene epoch, millions of years before modern humans appeared. The result is that human blood carries uric acid concentrations roughly ten times what you see in other mammals.1PubMed Central. Ancient insights into uric acid metabolism in primates The Dalmatian is an interesting parallel: a mutation in the SLC2A9 gene disrupts uric acid transport in both the liver and kidney, leading to high blood and urinary uric acid and a breed-wide tendency to form urate stones.2PubMed Central. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog
Why would evolution let this happen? The leading hypothesis is that losing uricase was not entirely bad. Uric acid is actually a potent antioxidant, and keeping higher circulating levels may have helped early primates survive on low-sodium, low-calorie diets by sustaining blood pressure and scavenging damaging free radicals. The problem is that these ancient benefits now collide with modern diets rich in fructose, purines, and alcohol, pushing uric acid levels far beyond what the body can gracefully handle.
Where Uric Acid Comes From and How It Leaves
Uric acid is the end product of purine metabolism. Purines come from two places: your own cells, which constantly break down and recycle DNA and RNA, and the food you eat, particularly organ meats, shellfish, and certain plant sources. An enzyme called xanthine oxidoreductase handles the final conversion steps, turning hypoxanthine into xanthine and then xanthine into uric acid.3PubMed Central. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview This enzyme comes in two forms: one that works quietly without producing much collateral damage, and another, xanthine oxidase, that generates reactive oxygen species as a byproduct, which matters because those free radicals contribute to tissue inflammation independent of uric acid itself.4PubMed. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity
Getting rid of uric acid is mostly the kidneys’ job, though the gut plays a supporting role. The kidney filters uric acid, reabsorbs most of it back into the blood, then secretes some of it again into the urine through a complicated dance of transport proteins. Key players include URAT1 and GLUT9, which pull uric acid back into the body, and ABCG2, OAT1, and OAT3, which push it out.5PubMed Central. Recent advances on uric acid transporters If any of these transporters malfunction, the balance tips toward accumulation. Some people reabsorb too much; others secrete too little. Either way, the result is the same: uric acid climbs.
The gut microbiome adds another layer. Certain gut bacteria can break down purines and uric acid directly, and disruptions to that microbial community reduce intestinal uric acid elimination. At the same time, elevated uric acid itself appears to shift the composition of gut bacteria in unfavorable ways, reducing diversity and weakening the intestinal barrier.6PubMed Central. Interactions between serum uric acid and gut microbiota: implications for metabolic health This creates a feedback loop: high uric acid damages the microbial ecosystem that would otherwise help keep it in check.
The Antioxidant Paradox
One of the confusing things about uric acid is that it genuinely is one of the body’s most important antioxidants. It accounts for a large share of the antioxidant capacity of human blood plasma, neutralizing harmful oxidants, chelating metals, and triggering adaptive protective responses against oxidative damage.7PubMed Central. Is uric acid a true antioxidant? Identification of uric acid oxidation products and their biological effects Yet at the same time, elevated uric acid consistently predicts the development of obesity, high blood pressure, and cardiovascular disease, all conditions associated with oxidative stress.8PubMed Central. Uric acid: the oxidant-antioxidant paradox
The resolution appears to be context-dependent. In the watery environment of blood plasma, uric acid behaves mostly as an antioxidant. But inside cells and in certain tissue microenvironments, particularly where inflammation is already active, it can flip to a pro-oxidant role, generating damaging byproducts rather than neutralizing them. Whether uric acid is friend or foe depends on where it is and what is happening around it. This duality makes it tricky to study and even trickier to make blanket treatment recommendations about.
Gout and the Temperature Connection
Gout is the most dramatic and recognizable consequence of hyperuricemia. When uric acid exceeds its solubility limit in blood, it can crystallize as monosodium urate crystals and deposit in joints and surrounding tissues. White blood cells attempt to engulf these crystals, which triggers a powerful inflammatory cascade through the NLRP3 inflammasome, releasing inflammatory signals that cause the intense pain, swelling, and redness of a gout flare.9PubMed Central. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout
There is a reason gout famously attacks the big toe. Uric acid crystallizes more readily at lower temperatures, and peripheral joints like the big toe, ankle, and knee run cooler than the body’s core. Research has shown that lower temperatures not only promote crystal formation without affecting how effectively immune cells swallow the crystals, but also enhance the inflammatory response itself. In other words, cooler joints get hit with a double penalty: more crystals form and each crystal triggers a bigger inflammatory reaction.10PubMed Central. Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout This also helps explain why gout attacks often strike at night, when extremities cool down during sleep.
Damage Beyond the Joints
Gout gets the most attention, but hyperuricemia’s reach extends well beyond swollen toes. Three areas stand out: kidney stones, cardiovascular damage, and chronic kidney disease progression.
Uric acid kidney stones form when urine is persistently too acidic, typically below a pH of about 5.5. At that acidity, uric acid stays in its undissociated form rather than dissolving, and it precipitates out as stones. Low urine volume and high uric acid excretion contribute, but the single most important driver is that persistently acidic urine.11PubMed. Uric acid nephrolithiasis: current concepts and controversies This is why uric acid stones are sometimes treated by alkalinizing the urine rather than by lowering uric acid itself, since raising urine pH above 6.0 can dissolve existing stones and prevent new ones.
On the cardiovascular side, animal and human studies show that high uric acid impairs the ability of blood vessel linings to relax properly. In animal models, hyperuricemia reduces nitric oxide availability in blood vessels, and this effect reverses when uric acid levels are brought down.12PubMed. Hyperuricemia induces endothelial dysfunction In a study of over 200 people with untreated high blood pressure, uric acid levels were independently linked to impaired blood vessel function even after accounting for other cardiovascular risk factors, with chronic inflammation appearing to mediate the connection.13Journal of the American Society of Nephrology. Uric Acid and Endothelial Dysfunction in Essential Hypertension
Hyperuricemia and kidney disease have a bidirectional relationship. Failing kidneys excrete less uric acid, which raises blood levels. But high uric acid itself appears to accelerate kidney damage through several mechanisms, including activating the renin-angiotensin system, inhibiting nitric oxide production, and stimulating oxidative stress inside kidney cells.14PubMed Central. Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy Observational data from the large KNOW-CKD study found that each 1 mg/dL increase in uric acid was associated with about a 35% higher risk of kidney disease progression. A recent study of people with stage 3 or worse kidney disease and hyperuricemia found that urate-lowering therapy was tied to a meaningfully lower three-year risk of kidney disease worsening and death.15Signal Transduction and Targeted Therapy. Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia
The liver gets pulled in too. Hyperuricemia and fatty liver disease appear to reinforce each other through insulin resistance. High insulin promotes both uric acid production and fat accumulation in the liver, while the resulting liver inflammation further reduces insulin sensitivity, creating a vicious cycle that damages blood vessels and amplifies metabolic dysfunction.16PubMed Central. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease
What Drives Uric Acid Up in the First Place
Diet is the most modifiable contributor, and alcohol is the biggest dietary culprit. Alcohol raises uric acid through several simultaneous routes: it accelerates the breakdown of purine-containing molecules inside cells, the lactic acid produced during alcohol metabolism competes with uric acid for excretion in the kidneys, and alcoholic beverages (especially beer) contain purines of their own.17PubMed. Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid) Not all drinks are equal. A study that standardized for ethanol content still found that beer and whiskey caused the largest spikes in uric acid, with wine producing a smaller effect and certain other spirits falling in between.18JAMA Network Open. Differences in the Association Between Alcoholic Beverage Type and Serum Urate Levels Using Standardized Ethanol Content Alcohol also appears to disrupt the gut microbiome in ways that further impair uric acid clearance.19PubMed Central. Impact of alcohol consumption on hyperuricemia and gout: a systematic review and meta-analysis
Fructose is the other major dietary driver, and it works differently from other sugars. When the liver metabolizes fructose, it rapidly consumes ATP (the cell’s energy currency), which generates a burst of purine breakdown products that funnel straight into uric acid production. This pathway links fructose intake to not just hyperuricemia but also to insulin resistance, fatty liver, high blood pressure, and obesity, with research suggesting these connections begin in childhood.20PubMed Central. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age Sugary sodas, fruit juices, and processed foods sweetened with high-fructose corn syrup are the main sources for most people.
Beyond diet, certain medications raise uric acid. Low-dose diuretics (commonly prescribed for blood pressure) are a well-known cause, as they increase uric acid reabsorption in the kidneys. Some immunosuppressive drugs, certain chemotherapy agents that cause rapid cell death, and organ transplant medications can also push levels up.
Genetic Susceptibility
Genetics accounts for a large portion of the variation in uric acid levels between people, and genome-wide studies have identified dozens of relevant gene variants. Two genes stand out: ABCG2 and SLC2A9, both of which encode uric acid transport proteins.
ABCG2 is a transporter that pumps uric acid out of the body through both the kidney and the gut. A common variant (rs2231142) that impairs this transporter’s function has been studied extensively, particularly in East Asian populations. A meta-analysis found that carrying one or two copies of the risk version of this variant was associated with roughly two to four and a half times the odds of developing gout, along with measurably higher blood uric acid levels.21PubMed Central. The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis In a Korean study, nearly 30% of gout patients carried the homozygous risk genotype compared to about 5% of controls.22PubMed Central. Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population
SLC2A9, which encodes the GLUT9 transporter, has the opposite story in some respects. Certain variants of this gene are actually protective, with carriers showing roughly 25 to 65% lower odds of gout and significantly lower serum uric acid compared to non-carriers. These protective variants have been mainly studied in people of European descent.23PubMed Central. The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis
At the extreme end of genetic hyperuricemia sits Lesch-Nyhan syndrome, a rare X-linked disorder caused by a deficiency in the enzyme that recycles purines. Children with this condition develop severe hyperuricemia along with neurological problems including involuntary movements and compulsive self-injury.24JAMA Dermatology. Hyperuricemia With Self-Mutilation and Choreo-Athetosis: Lesch-Nyhan Syndrome It is vanishingly rare, but it illustrates how deeply purine metabolism is wired into biology beyond joint health.
Treatment Approaches
When hyperuricemia needs treatment, there are three broad pharmacological strategies, each targeting a different part of the problem.
- Reducing production: Xanthine oxidase inhibitors like allopurinol and febuxostat block the enzyme that creates uric acid. Febuxostat is a particularly potent inhibitor that works on both forms of the enzyme.25PubMed. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase Allopurinol remains the most commonly prescribed first-line drug worldwide, mostly because of its long track record and low cost.
- Increasing excretion: Uricosuric drugs work on kidney transporters to push more uric acid into the urine. Lesinurad, for example, blocks both URAT1 and OAT4 in the kidney.26PubMed Central. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney Newer agents like dotinurad are far more potent at inhibiting URAT1 specifically.27PubMed. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor Adequate hydration is essential with these drugs, since flooding the kidneys with uric acid can increase stone risk.
- Breaking uric acid down: For severe, refractory gout where other treatments have failed, injectable uricase enzymes like pegloticase and rasburicase can convert uric acid into allantoin, essentially doing what our lost uricase gene would have done. These are considered a last resort because they require infusions and carry a risk of allergic reactions.28Exploration of Musculoskeletal Diseases. Uricases: reflections on recent developments in the management of challenging gout patients
Lifestyle modifications accompany all of these: reducing alcohol (especially beer), cutting back on high-fructose foods, staying well-hydrated, and maintaining a healthy weight. Dairy products and coffee are two dietary factors consistently associated with lower uric acid levels, though neither is a substitute for medication when levels are significantly elevated.
The Debate Over Treating Asymptomatic Hyperuricemia
One of the most contentious questions in this field is what to do when someone has high uric acid on a blood test but no gout, no stones, and no symptoms. This is called asymptomatic hyperuricemia, and it is far more common than gout itself. The argument for treatment rests on the associations described above: if elevated uric acid damages kidneys, blood vessels, and the liver, shouldn’t you lower it before those problems develop?
The evidence is genuinely mixed. Recent data from people with chronic kidney disease and hyperuricemia showed that urate-lowering therapy was associated with lower rates of kidney disease progression.29Signal Transduction and Targeted Therapy. Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia But a careful review of the field concluded that because urate-lowering drugs carry their own risks (allopurinol can cause severe hypersensitivity reactions, and all medications put additional stress on already-compromised kidneys), it is premature to broadly recommend pharmacological treatment for asymptomatic hyperuricemia in kidney disease patients. Conclusive evidence that these drugs protect kidneys in people with less severe disease and no symptoms is still lacking.30Kidney Research and Clinical Practice. To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease
Practice varies sharply by region. In Japan, for example, guidelines have been more aggressive about treating asymptomatic hyperuricemia than in the United States or Europe, where most professional societies recommend treatment only for people who have had gout attacks, uric acid stones, or very high levels with other risk factors. The honest answer for now is that the science has not yet caught up with the question, and reasonable clinicians disagree.
When the Problem Starts Early
Hyperuricemia is not just an adult problem. The connections between fructose, uric acid, and metabolic dysfunction begin in childhood, and pediatric researchers have raised alarms about rising uric acid levels in children and adolescents, particularly those with obesity. High fructose intake in young people has been linked through shared biological pathways to insulin resistance, elevated blood pressure, and early fatty liver changes, with uric acid playing a central mediating role.31PubMed Central. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age Pediatric gout remains rare, but the metabolic consequences of chronically elevated uric acid may be setting the stage for cardiovascular and kidney problems decades later. Screening and intervention guidelines for children are still underdeveloped compared to adult medicine, which means many young people with elevated uric acid are not being identified or tracked.